EnBiotix purchases AMP Therapeutics' anti-microbial peptide portfolio
EnBiotix has completed an asset acquisition of AMP Therapeutics (AMPT), an anti-microbial peptide portfolio firm of Boehringer Ingelheim Venture Fund and Novartis Venture Fund.
top of page
bottom of page